SCHEDULE: Nan Fung Group Discloses Significant Evommune Stake

Nan Fung Group Holdings Limited and its affiliated entities have disclosed beneficial ownership of up to 10.9% of Evommune, Inc.'s common stock.

Summary

• Nan Fung Group Holdings Limited, along with several affiliated entities, has filed a Schedule 13G indicating significant beneficial ownership in Evommune, Inc.
• Nan Fung Group Holdings Limited beneficially owns 3,435,599 shares, representing 10.9% of Evommune's common stock.
• NF Investment Holdings Limited and Nan Fung Life Sciences Holdings Limited each beneficially own 3,367,975 shares, equating to 10.7% of the class.
• Pivotal Life Sciences Holdings Limited and Pivotal Partners Ltd each beneficially own 1,926,943 shares, representing 6.1% of the class.
• Pivotal bioVenture Partners Fund I U.G.P. Ltd, Pivotal bioVenture Partners Fund I G.P., L.P., and Pivotal bioVenture Partners Fund I, L.P. each beneficially own 1,632,441 shares, representing 5.2% of the class.
• The ownership percentages are based on 31,524,093 shares of Evommune, Inc. common stock outstanding as of December 10, 2025.
• The reporting persons disclaim beneficial ownership of 67,624 shares held by Messrs. Bisgaard, Hopfner, and Vincent Sai Sing Cheung, which are included in NFGHL's aggregate amount.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The disclosure of significant institutional ownership by a reputable group suggests a vote of confidence in Evommune, Inc., which can be a positive signal for other investors.

Positives

• The disclosure of significant beneficial ownership by a large institutional group like Nan Fung Group and its affiliates can signal confidence in Evommune, Inc.'s long-term prospects.
• Multiple entities within the Nan Fung Group and Pivotal bioVenture Partners hold substantial stakes, indicating a coordinated investment strategy.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by a prominent investment group like Nan Fung Group, particularly through its life sciences arms, indicates a strategic long-term investment in Evommune, Inc. This type of disclosure is common for passive institutional investors who hold more than 5% of a company's stock, signaling their belief in the company's potential within the biotechnology sector.

Related Party Transactions

• The filing details a complex hierarchical ownership structure where Nan Fung Group Holdings Limited ultimately controls several entities, including NF Investment Holdings Limited and Nan Fung Life Sciences Holdings Limited.
• Nan Fung Life Sciences Holdings Limited, in turn, controls NFLS Platform Holdings Limited and Pivotal Life Sciences Holdings Limited.
• Pivotal Life Sciences Holdings Limited controls Pivotal Partners Ltd, which then controls the general partners of Pivotal bioVenture Partners Fund I and Fund II.
• NFLS Platform Holdings Limited controls NFLS Delta Limited, which controls NFLS Delta III Limited.
• Investment decisions for the Issuer's securities held by NFLS Delta III are made by the Executive Committee of NFGHL.
• Investment decisions for the Issuer's securities held by Pivotal I and Pivotal II are made by the Executive Committee and the Life Sciences Committee of NFGHL.

Stakeholder Impact

• Shareholders may view this as a positive indicator, as significant institutional investment often implies thorough due diligence and a belief in the company's value.
• The presence of a large, coordinated institutional investor group could provide a degree of stability to the stock.

Key Dates

Keywords

Evommune Inc, Nan Fung Group Holdings Limited, Pivotal bioVenture Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Life Sciences